Poolbeg Pharma (LON:POLB) Shares Down 6.4% – What’s Next?

Poolbeg Pharma PLC (LON:POLB) shares dropped 6.4% during trading on Monday . The company traded as low as GBX 7.60 and last traded at GBX 8.05. Approximately 3,195,051 shares traded hands during mid-day trading, an increase of 96% from the average daily volume of 1,628,823 shares. The stock had previously closed at GBX 8.60.

Analysts Set New Price Targets

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Tuesday, May 26th.

Poolbeg Pharma Stock Performance

The stock’s 50-day moving average is GBX 4.93 and its 200 day moving average is GBX 4.47. The firm has a market cap of £56.76 million, a P/E ratio of -8.56 and a beta of 1.78.

Poolbeg Pharma (LON:POLB) last released its earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share (EPS) for the quarter. On average, research analysts anticipate that Poolbeg Pharma PLC will post -0.68 EPS for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.